TP53 and neoplasm: Additionally, of the less-studied biomarkers, the most promising are cfDNA-level alterations or copy number loss in the three tumor suppressors PTEN, RB1, and TP53, which are supported by the most evidence and more consistent results across studies; additionally, the prevalence of each of the three alterations is sufficiently high for practical application.